Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Elan Outlines Options For Tysabri If Biogen Idec Is Sold

This article was originally published in The Pink Sheet Daily

Executive Summary

Larger pharmas, including Pfizer and Johnson & Johnson, are likely among the potential acquirers.

You may also be interested in...

Biogen Hires Outside Help To Evaluate Acquisition Interest

Activist investor Carl Icahn is among those interested in the biotech.

Joint Panel Recommends Tysabri For Crohn’s Disease

The highly restricted Tysabri risk management program tipped the risk-benefit scale in Biogen Idec/Elan’s favor.

Tysabri To Be Priced 20% Higher Than When Initially Launched

Biogen CFO predicts favorable reimbursement for natalizumab, minimizing cost for most patients.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts